Curriculum Group Wraps up Inaugural Fellows’ Training Series
Our national neuromuscular lecture series launched last August 2022 has just wrapped up! The series consisted of a weekly (38 weeks) virtual Royal College CPD-accredited curriculum for neuromuscular fellows presented by subject-matter experts, developed by the curriculum working group together with the directors of fellowship programs across Canada.
In total, 33 neuromuscular fellows participated in the inaugural lecture series, from adult and pediatric neuromuscular and physiatry fellowship programs from across Canada. The pilot lecture series received extremely positive feedback, with fellows sharing that the series was informative, applicable to their practice, and indicated a high degree of satisfaction overall.
Building on this successful collaboration between Canadian fellowship programs, the planning committee is currently preparing the second iteration of the program, set to begin in mid-August 2023 for a new cohort of Canadian neuromuscular fellows.
For more information, please contact network administrative coordinator James Davis at .
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.